New drug aims to help kids with rare genetic short stature grow taller
NCT ID NCT04219007
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called vosoritide in 56 children with short stature caused by certain genetic conditions. The drug targets the growth plate to help children grow faster. Participants are observed for 6 months, then treated with daily injections for 12 months to check safety and growth improvement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACAN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's National Hospital
Washington D.C., District of Columbia, 20010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World study tracks Selumetinib's impact on NF1 tumors in children
- Could a cholesterol drug boost reading skills in kids with NF1?
- Scientists dive into cells to unravel costello Syndrome's secrets
- Antioxidant drug shows promise for kids with NF1
- Can a simple walk test spot motor trouble in kids with NF1?
- New study tracks Long-Term safety of NF1 drug in kids